- Home
- HUMA vs NYXH Comparison
HUMA vs NYXH Comparison
Compare HUMA & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HUMA | NYXH |
|---|---|---|
| Founded | 2004 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.6M | 188.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | HUMA | NYXH |
|---|---|---|
| Price | $1.07 | $4.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 3 |
| Target Price | $10.00 | ★ $12.67 |
| AVG Volume (30 Days) | ★ 5.4M | 44.9K |
| Earning Date | 11-12-2025 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,571,000.00 | ★ $6,616,215.00 |
| Revenue This Year | N/A | $75.27 |
| Revenue Next Year | $731.05 | $277.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 10.96 |
| 52 Week Low | $0.91 | $4.35 |
| 52 Week High | $4.85 | $11.87 |
Technical Indicators
Market Signals| Indicator | HUMA | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 45.11 | 46.63 |
| Support Level | $0.96 | $4.66 |
| Resistance Level | $1.15 | $5.00 |
| Average True Range (ATR) | 0.09 | 0.23 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 33.20 | 33.33 |
Price Performance
Historical ComparisonAbout HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.